MedTrace Logo

Effect of Covid 19 Infection on Fetomaternal Outcome

NCT05160649 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-04-28

No results posted yet for this study

Summary

The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered for the first time in December 2019 in Wuhan (China) and the disease it causes is called coronavirus disease 2019 (COVID-19). Now, this pandemic is rapidly spreading all over the world.

Pregnant have higher rates of COVID-19, associated with hospitalizations, and severe in-hospital outcomes. Immune responses may have a potential role in the diagnosis, treatment, and prognosis of patients with COVID-19. So we need of identifying biomarkers for disease severity and progression.

Conditions

Sponsors & Collaborators

  • Fayoum University

    lead OTHER

Principal Investigators

  • Laila E Abdelfattah, Ass. prof · Associated professor of obestatrics and gynecology Faculty of medicine Fayoume university

  • Eman E Mahmoud, lecturer · Lecturer of clinical and chemical pathology

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-10
Primary Completion
2023-06-30
Completion
2023-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05160649 on ClinicalTrials.gov